Repositorio
Institucional

Salazar, Luis A.

Loren, Pia

Saavedra, Nicolas

Saavedra, Kathleen

Torso, Nadine De Godoy

Visacri, Marilia Berlofa

Moriel, Patricia

Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review

FRONTIERS MEDIA SA

FRONTIERS IN PHARMACOLOGY

en

Cisplatin (DDP) is a well-known anticancer drug used for the treatment of numerous human cancers in solid organs, including bladder, breast, cervical, head and neck squamous cell, ovarian, among others. Its most important mode of action is the DNA-platinum adducts formation, inducing DNA damage response, silencing or activating several genes to induce apoptosis, these mechanisms result in genetics and epigenetics modifications. The ability of DDP to induce tumor cell death is often challenged by the presence of anti-apoptotic regulators, leading to chemoresistance, wherein many patients who have or will develop DDP-resistance. Cancer cells resist the apoptotic effect of chemotherapy, being a problem that severely restricts the successful results of treatment for many human cancers. In the last 30 years, researchers have discovered there are several types of RNAs, and among the most important are non-coding RNAs (ncRNAs), a class of RNAs that are not involved in protein production, but they are implicated in gene expression regulation, and representing the 98% of the human genome non-translated. Some ncRNAs of great interest are long ncRNAs, circular RNAs, and microRNAs (miRs). Accumulating studies reveal that aberrant miRs expression can affect the development of chemotherapy drug resistance, by modulating the expression of relevant target proteins. Thus, identifying molecular mechanisms underlying chemoresistance development is fundamental for setting strategies to improve the prognosis of patients with different types of cancer. Therefore, this review aimed to identify and summarize miRs that modulate chemoresistance in DDP-resistant in the top five deadliest cancer, both in vitro and in vivo human models.

artículo de revisión

This research was funded by ANID-FAPESP (Grant No. 19/132501), FONDECYT (Grant No. 1171765), Programa de Formacion de Investigadores Postdoctorales, VRIP, Universidad de La Frontera, Temuco, Chile (Code VRIP 21001) and FONDECYT Postdoctoral Grant No. 3220404 awarded to PL.

10.3389/fphar.2022.831099

PDF

microRNA

drug-resistance

cisplatin

sensitivity

cancer

CELL LUNG-CANCER

EPITHELIAL-MESENCHYMAL TRANSITION

HUMAN GASTRIC-CANCER

NF-KAPPA-B

MODULATES MULTIDRUG-RESISTANCE

NONSMALL CELL

HEPATOCELLULAR-CARCINOMA

COLORECTAL-CANCER

DRUG-RESISTANCE

ADENOCARCINOMA CELLS

Farmacología y farmacia

microARN

resistencia a medicamentos

cisplatino

sensibilidad

cáncer

CÉLULAS DE CÁNCER DE PULMÓN

TRANSICIÓN EPITELIAL-MESENQUIMAL

CÁNCER GÁSTRICO HUMANO

NF-KAPPA-B

MODULA LA RESISTENCIA A MULTIDROGAS

CÉLULAS NO PEQUEÑAS

CARCINOMA-HEPATOCELULAR

CÁNCER-COLORECTAL

DROGAS -CÉLULAS DE RESISTENCIA

ADENOCARCINOMA

Oncología

Farmacología y Farmacia

Biología Molecular

version publicada

dorada

verde

acceso abierto

acceso abierto

WOS:000790481800001

Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review

artículo de revisión

CC BY 4.0

CC BY 4.0

ANID-FONDECYT 1171765

ANID-FONDECYT 3220404

ANID-FAPESP 19/132501

UFRO VRIP21001

ANID FONDECYT 1171765

ANID FONDECYT 3220404

ANID FAPESP 19/132501